SNU안과 offers various eye surgeries including smile surgery, lens implantation, and treatment for presbyopia and cataracts, self-described as a provider of advanced eye care solutions.

SNU안과

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Alcon Inc.

Bausch Health develops, manufactures, and markets a range of pharmaceutical products and medical devices, self-described as enriching lives through a relentless drive to deliver better health outcomes.

Metric
Company Name	SNU안과	AbbVie Inc.	Alcon Inc.	Bausch Health
Symbol		ABBV	ALC
MSH ID	COM:SNUSEOUL	COM:ABBVIE	COM:ALCON	COM:BAUSCHHEALTH
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare		Healthcare & Health Services
Industry	Medical Services	Drug Manufacturers - General		Pharmaceuticals
Country	KR	US	CH	CA
Stage
Employee Count		50K	25K
Website	snuseoul.com	abbvie.com	alcon.com	bauschhealth.com
LinkedIn
Founders

Metric
Market Cap	296.91B	37.60B
Enterprise Value
Monthly Web Traffic	1.18M	293
Web Traffic Growth	0.51	-0.72
Valuation
Raised Capital	15B

Metric
Revenue	54.32B	9.46B
Revenue (LTM)
Revenue (NTM)
Gross Profit	45.54B	5.25B
EBITDA	18.10B	2.29B
Operating Income	17.43B	1.04B
Net Income	4.86B	974M
EPS	2.75	1.98
Diluted EPS	2.74	1.98
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.72	0.56
Operating Profit Margin	0.27	0.12
EBITDA Margin	0.33	0.24
Net Profit Margin	0.11	0.11
Return on Equity	0.57	0.10
Return on Assets	0.04	0.04
Return on Capital Employed	0.15	0.04

COM:SNUSEOUL

SNU안과

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	46.58	82.75
P/B Ratio	25.09	1.89
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.36	5.16
EV Multiple	17.44	36.34

Metric
Days Sales Outstanding	75.54	66.36
Days Payables Outstanding		75.78
Days Inventory Outstanding	102.41	201.41
Operating Cycle	181.71	282.86
Cash Conversion Cycle	179.57	212.52
Asset Turnover	0.40	0.32

Metric
Operating Cash Flow	22.84B	1.39B
Free Cash Flow	22.06B	537M
Cash Flow to Debt	0.38	0.36
Operating Cash Flow/Sales	0.42	0.19
Free Cash Flow Yield	0.08	0.01

Metric
Cash & Equivalents	12.81B	1.09B
Accounts Receivable	66M	-110M
Inventory	4.10B	2.32B
Goodwill	32.29B	8.93B
Debt to Capitalization	0.91	0.20
Debt to Assets	0.45	0.17
Current Ratio	0.96	1.87
Quick Ratio	0.83	1.56

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.01
R&D to Revenue	0.14	0.09
SG&A to Revenue